Page 31 - Read Online

Page 12 of 12 Mansinho et al. J Cancer Metastasis Treat 2021;7:44 https://dx.doi.org/10.20517/2394-4722.2021.88

58. Guillot A, Joly C, Barthélémy P, et al. Denosumab toxicity when combined with anti-angiogenic therapies on patients with metastatic
renal cell carcinoma: a GETUG study. Clin Genitourin Cancer 2019;17:e38-43. DOI PubMed
59. Fusco V, Porta C, Saia G, et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and
targeted agents: results of an italian multicenter study and review of the literature. Clin Genitourin Cancer 2015;13:287-94. DOI
PubMed
60. McKay RR, Bossé D, Gray KP, et al. Radium-223 dichloride in combination with vascular endothelial growth factor-targeting therapy
in advanced renal cell carcinoma with bone metastases. Clin Cancer Res 2018;24:4081-8. DOI PubMed PMC
61. Beisland C, Johannesen TB, Klepp O, et al. Overall survival in renal cell carcinoma after introduction of targeted therapies: a
Norwegian population-based study. Onco Targets Ther 2017;10:371-85. DOI PubMed PMC
62. Chang AJ, Zhao L, Zhu Z, et al. The past, present and future of immunotherapy for metastatic renal cell carcinoma. Anticancer Res
2019;39:2683-7. DOI PubMed
63. Schultze-Seemann W, Schulz H, Tschechne B, Häckl M. Bevacizumab plus IFN-alpha-2a in first-line treatment of patients with
advanced or metastatic renal cell carcinoma: a prospective German non-interventional study. Anticancer Res 2019;39:875-82. DOI
PubMed
64. Maita, S. et al. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Int J Cancer 2012;130:677-84. DOI PubMed
65. Kalra S, Verma J, Atkinson BJ, et al. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted
therapy era. Clin Genitourin Cancer 2017;15:363-70. DOI PubMed
66. Zołnierek J, Nurzyński P, Langiewicz P, et al. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or
new bone metastases. J Cancer Res Clin Oncol 2010;136:371-78. DOI PubMed
67. Choueiri TK, Escudier B, Powles T, et al; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell
Carcinoma. N Engl J Med 2015;373:1814-23. DOI PubMed PMC
68. Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a New Standard of care for patients with advanced renal cell carcinoma and
bone metastases? J Clin Oncol 2018;36:765-72. DOI PubMed PMC
69. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell
carcinoma. N Engl J Med 2015;373:1803-13. DOI PubMed PMC
70. Fioramonti M, Santini D, Iuliani M, et al. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast
functions. Oncotarget 2017;8:20113-21. DOI PubMed PMC
71. Escudier B, Sharma P, McDermott DF, et al; CheckMate 025 investigators. CheckMate 025 randomized phase 3 study: outcomes by
key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol 2017;72:962-71.
DOI PubMed
72. Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Denosumab and pembrolizumab in clear cell renal
carcinoma: a Phase II Trial (ANZUP 1601). Available from: https://clinicaltrials.gov/ct2/show/NCT03280667 [Last accessed on 6 Jul
2021].
73. Motzer RJ, Jonasch E, Michaelson MD, et al. NCCN guidelines insights: kidney cancer, version 2.2020. J Natl Compr Canc Netw
2019;17:1278-85. DOI PubMed
74. Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided
intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2012;82:1744-8.
DOI PubMed PMC
75. Jhaveri PM, Teh BS, Paulino AC, et al. A dose-response relationship for time to bone pain resolution after stereotactic body
radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases. Acta Oncol 2012;51:584-8. DOI PubMed
76. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without
spinal cord compression: a phase 1-2 trial. Lancet Oncol 2012;13:395-402. DOI PubMed PMC
77. Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol
2014;15:e549-61. DOI PubMed
78. Du Y, Pahernik S, Hadaschik B, et al. Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era
of targeted therapy: a single-institution analysis. Urol Oncol 2016;34:433.e1-8. DOI PubMed
79. Kato S, Murakami H, Demura S, et al. Spinal metastasectomy of renal cell carcinoma: a 16-year single center experience with a
minimum 3-year follow-up. J Surg Oncol 2016;113:587-92. DOI PubMed
80. Hunter GK, Balagamwala EH, Koyfman SA, et al. The efficacy of external beam radiotherapy and stereotactic body radiotherapy for
painful spinal metastases from renal cell carcinoma. Pract Radiat Oncol 2012;2:e95-e100. DOI PubMed
81. Teyssonneau D, Gross-Goupil M, Domblides C, et al. Treatment of spinal metastases in renal cell carcinoma: a critical review. Crit
Rev Oncol Hematol 2018;125:19-29. DOI PubMed